{
  "symbol": "VKTX",
  "company_name": "Viking Thera",
  "ir_website": "https://ir.vikingtherapeutics.com/",
  "structured_data": [
    {
      "section_name": "News & Events",
      "links": [
        {
          "title": "News & Events",
          "url": "https://ir.vikingtherapeutics.com/press-releases",
          "content": "[![Viking Therapeutics](https://www.vikingtherapeutics.com/wp-content/uploads/viking-logo-top-3.png)](http://www.vikingtherapeutics.com/)\n\n# News & Events\n\n![Investors](images/section-stock-1024x262.jpg)\n\n  * [ Overview ](https://ir.vikingtherapeutics.com/overview)\n  * [ Stock Information ](https://ir.vikingtherapeutics.com/stock-information)\n  * [ News & Events ](press-releases)\n    * [ Press Releases ](https://ir.vikingtherapeutics.com/press-releases)\n    * [ Webcasts ](https://ir.vikingtherapeutics.com/webcasts)\n  * [ SEC Filings ](https://ir.vikingtherapeutics.com/sec-filings)\n  * [ Analyst Coverage ](https://ir.vikingtherapeutics.com/analyst-coverage)\n  * [ Corporate Governance ](governance-highlights)\n  * [ Shareholder Services ](information-request)\n  * [ Corporate Presentation ](https://ir.vikingtherapeutics.com/corporatepresentation)\n\n[Sign Up for Email Alerts](email-alerts) [Investor Relations Contacts](ir-contacts)\n\nMonth Year \n\nSu  |  Mo  |  Tu  |  We  |  Th  |  Fr  |  Sa   \n---|---|---|---|---|---|---  \n25  |  26  |  27  |  28  |  29  |  30  |  1   \n2  |  3  |  4  |  5  |  6  |  7  |  8   \n9  |  10  |  11  |  12  |  13  |  14  |  15   \n16  |  17  |  18  |  19  |  20  |  21  |  22   \n23  |  24  |  25  |  26  |  27  |  28  |  29   \n30  |  31  |  1  |  2  |  3  |  4  |  5   \n  \nCancel  Go\n\nMonth Year \n\nSu  |  Mo  |  Tu  |  We  |  Th  |  Fr  |  Sa   \n---|---|---|---|---|---|---  \n25  |  26  |  27  |  28  |  29  |  30  |  1   \n2  |  3  |  4  |  5  |  6  |  7  |  8   \n9  |  10  |  11  |  12  |  13  |  14  |  15   \n16  |  17  |  18  |  19  |  20  |  21  |  22   \n23  |  24  |  25  |  26  |  27  |  28  |  29   \n30  |  31  |  1  |  2  |  3  |  4  |  5   \n  \nCancel  Go\n\n[ E-mail Alerts![](images/webdriver/email_alerts.png) ](https://ir.vikingtherapeutics.com/email-alerts?type=1)\n\nYear All Years 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 Keywords Go\n\n[Advanced Search](#)\n\nSearch\n\nSearch Headlines Only\n\nFrom\n\nTo\n\nAsset Types\n\nVideo Audio Photos Documents Events Standard\n\n[Basic Search](#)\n\n  * Nov 19, 2024\n\n[Viking Therapeutics Presents Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting速 2024](https://ir.vikingtherapeutics.com/2024-11-19-Viking-Therapeutics-Presents-Results-from-Phase-2b-VOYAGE-Study-of-VK2809-in-Biopsy-Confirmed-NASH-MASH-at-the-75th-Liver-Meeting-R-2024)\n\nOral Late Breaker Presentation Summarizes Positive Results Including Successful Achievement of Study's Primary and Secondary Endpoints Data Support VK2809's Best-in-Class Profile Highlighted by...\n\n  * Nov 12, 2024\n\n[Viking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting速 2024](https://ir.vikingtherapeutics.com/2024-11-12-Viking-Therapeutics-to-Present-Data-from-Phase-2b-VOYAGE-Study-of-VK2809-in-Patients-with-Biopsy-Confirmed-NASH-MASH-at-the-75th-Liver-Meeting-R-2024)\n\nViking Therapeutics, Inc. (\"Viking\") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...\n\n  * Nov 4, 2024\n\n[Viking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek速 2024](https://ir.vikingtherapeutics.com/2024-11-04-Viking-Therapeutics-Reports-New-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2024)\n\nUp to 6.8% Placebo-Adjusted Mean Weight Loss (8.2% from Baseline) After 28 Days of Dosing with Oral Tablet of VK2735 Encouraging Tolerability Through 100 mg Daily Dosing with Oral VK2735; Mild...\n\n  * Oct 31, 2024\n\n[Viking Therapeutics to Participate at Upcoming Investor Conferences](https://ir.vikingtherapeutics.com/2024-10-31-Viking-Therapeutics-to-Participate-at-Upcoming-Investor-Conferences)\n\nViking Therapeutics, Inc. (\"Viking\") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...\n\n  * Oct 28, 2024\n\n[Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek速 2024](https://ir.vikingtherapeutics.com/2024-10-28-Viking-Therapeutics-to-Highlight-Clinical-Data-from-VK2735-Obesity-Program-in-Presentations-at-ObesityWeek-R-2024)\n\nResults from VENTURE Phase 2 Study of Subcutaneous VK2735 in Obese Patients and Phase 1 Trial of Oral VK2735 in Healthy Subjects to be Presented SAN DIEGO, Oct. 28, 2024 /PRNewswire/ -- Viking...\n\n\n\n\nLoad More\n\nLoading...\n"
        }
      ]
    },
    {
      "section_name": "SEC Filings",
      "links": [
        {
          "title": "SEC Filings",
          "url": "https://ir.vikingtherapeutics.com/sec-filings",
          "content": "[![Viking Therapeutics](https://www.vikingtherapeutics.com/wp-content/uploads/viking-logo-top-3.png)](http://www.vikingtherapeutics.com/)\n\n# SEC Filings\n\n![Investors](images/section-stock-1024x262.jpg)\n\n  * [ Overview ](https://ir.vikingtherapeutics.com/overview)\n  * [ Stock Information ](https://ir.vikingtherapeutics.com/stock-information)\n  * [ News & Events ](press-releases)\n  * [ SEC Filings ](https://ir.vikingtherapeutics.com/sec-filings)\n  * [ Analyst Coverage ](https://ir.vikingtherapeutics.com/analyst-coverage)\n  * [ Corporate Governance ](governance-highlights)\n  * [ Shareholder Services ](information-request)\n  * [ Corporate Presentation ](https://ir.vikingtherapeutics.com/corporatepresentation)\n\n[Sign Up for Email Alerts](email-alerts) [Investor Relations Contacts](ir-contacts)\n\nSelect the filing type and date range you wish to view from the drop-down menus below.\n\nNASDAQVKTX\n\nYear\n\nTrailing 12-Months\n\nView\n\nAll Filings\n\nForm| Description| Date| Format  \n---|---|---|---  \nSC 13G/A| Amendment to a previously filed SC 13G| Nov 14, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Amendment to a previously filed SC 13G in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318722286&type=HTML&symbol=VKTX&cdn=1d840653ddf5bfc2359680a9a434ff06&companyName=Viking+Therapeutics+Inc.&formType=SC+13G%2FA&dateFiled=2024-11-14)[![](images/webdriver/fileicons/16/sec_doc.png)Open Amendment to a previously filed SC 13G in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318722286&type=DOC&symbol=VKTX&cdn=1d840653ddf5bfc2359680a9a434ff06&companyName=Viking+Therapeutics+Inc.&formType=SC+13G%2FA&dateFiled=2024-11-14)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Amendment to a previously filed SC 13G in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318722286&type=PDF&symbol=VKTX&cdn=1d840653ddf5bfc2359680a9a434ff06&companyName=Viking+Therapeutics+Inc.&formType=SC+13G%2FA&dateFiled=2024-11-14)[![](images/webdriver/fileicons/16/sec_xls.png)Open Amendment to a previously filed SC 13G in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318722286&type=XLS&symbol=VKTX&cdn=1d840653ddf5bfc2359680a9a434ff06&companyName=Viking+Therapeutics+Inc.&formType=SC+13G%2FA&dateFiled=2024-11-14)  \nSC 13G/A| Amendment to a previously filed SC 13G| Nov 12, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Amendment to a previously filed SC 13G in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318710341&type=HTML&symbol=VKTX&cdn=df838be09b6890222751d12a068f7ebb&companyName=Viking+Therapeutics+Inc.&formType=SC+13G%2FA&dateFiled=2024-11-12)[![](images/webdriver/fileicons/16/sec_doc.png)Open Amendment to a previously filed SC 13G in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318710341&type=DOC&symbol=VKTX&cdn=df838be09b6890222751d12a068f7ebb&companyName=Viking+Therapeutics+Inc.&formType=SC+13G%2FA&dateFiled=2024-11-12)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Amendment to a previously filed SC 13G in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318710341&type=PDF&symbol=VKTX&cdn=df838be09b6890222751d12a068f7ebb&companyName=Viking+Therapeutics+Inc.&formType=SC+13G%2FA&dateFiled=2024-11-12)[![](images/webdriver/fileicons/16/sec_xls.png)Open Amendment to a previously filed SC 13G in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318710341&type=XLS&symbol=VKTX&companyName=Viking+Therapeutics+Inc.&formType=SC+13G%2FA&dateFiled=2024-11-12)  \n144| Non-EDGAR filing submitted by \"insiders\" prior to intended sale of restricted stock| Nov 8, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Non-EDGAR filing submitted by \"insiders\" prior to intended sale of restricted stock in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318703110&type=HTML&symbol=VKTX&cdn=1f21f9c97ead9b6575493137daf7ef62&companyName=Viking+Therapeutics+Inc.&formType=144&dateFiled=2024-11-08)[![](images/webdriver/fileicons/16/sec_doc.png)Open Non-EDGAR filing submitted by \"insiders\" prior to intended sale of restricted stock in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318703110&type=DOC&symbol=VKTX&cdn=1f21f9c97ead9b6575493137daf7ef62&companyName=Viking+Therapeutics+Inc.&formType=144&dateFiled=2024-11-08)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Non-EDGAR filing submitted by \"insiders\" prior to intended sale of restricted stock in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318703110&type=PDF&symbol=VKTX&cdn=1f21f9c97ead9b6575493137daf7ef62&companyName=Viking+Therapeutics+Inc.&formType=144&dateFiled=2024-11-08)[![](images/webdriver/fileicons/16/sec_xls.png)Open Non-EDGAR filing submitted by \"insiders\" prior to intended sale of restricted stock in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318703110&type=XLS&symbol=VKTX&companyName=Viking+Therapeutics+Inc.&formType=144&dateFiled=2024-11-08)  \n4| Statement of changes in beneficial ownership of securities| Nov 8, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Statement of changes in beneficial ownership of securities in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318703122&type=HTML&symbol=VKTX&cdn=100a7c7e74655a18183fb3eb20d359fb&companyName=Viking+Therapeutics+Inc.&formType=4&dateFiled=2024-11-08)[![](images/webdriver/fileicons/16/sec_doc.png)Open Statement of changes in beneficial ownership of securities in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318703122&type=DOC&symbol=VKTX&cdn=100a7c7e74655a18183fb3eb20d359fb&companyName=Viking+Therapeutics+Inc.&formType=4&dateFiled=2024-11-08)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Statement of changes in beneficial ownership of securities in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318703122&type=PDF&symbol=VKTX&cdn=100a7c7e74655a18183fb3eb20d359fb&companyName=Viking+Therapeutics+Inc.&formType=4&dateFiled=2024-11-08)[![](images/webdriver/fileicons/16/sec_xls.png)Open Statement of changes in beneficial ownership of securities in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318703122&type=XLS&symbol=VKTX&cdn=100a7c7e74655a18183fb3eb20d359fb&companyName=Viking+Therapeutics+Inc.&formType=4&dateFiled=2024-11-08)  \nSC 13G/A| Amendment to a previously filed SC 13G| Nov 4, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Amendment to a previously filed SC 13G in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318685742&type=HTML&symbol=VKTX&cdn=fee948ea7f33b805268c7ce876f6be21&companyName=Viking+Therapeutics+Inc.&formType=SC+13G%2FA&dateFiled=2024-11-04)[![](images/webdriver/fileicons/16/sec_doc.png)Open Amendment to a previously filed SC 13G in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318685742&type=DOC&symbol=VKTX&cdn=fee948ea7f33b805268c7ce876f6be21&companyName=Viking+Therapeutics+Inc.&formType=SC+13G%2FA&dateFiled=2024-11-04)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Amendment to a previously filed SC 13G in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318685742&type=PDF&symbol=VKTX&cdn=fee948ea7f33b805268c7ce876f6be21&companyName=Viking+Therapeutics+Inc.&formType=SC+13G%2FA&dateFiled=2024-11-04)[![](images/webdriver/fileicons/16/sec_xls.png)Open Amendment to a previously filed SC 13G in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318685742&type=XLS&symbol=VKTX&companyName=Viking+Therapeutics+Inc.&formType=SC+13G%2FA&dateFiled=2024-11-04)  \n8-K| Report of unscheduled material events or corporate event| Nov 4, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Report of unscheduled material events or corporate event in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318684372&type=HTML&symbol=VKTX&cdn=a1f258bfbf8c64f83122b822569029c4&companyName=Viking+Therapeutics+Inc.&formType=8-K&dateFiled=2024-11-04)[![](images/webdriver/fileicons/16/sec_doc.png)Open Report of unscheduled material events or corporate event in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318684372&type=DOC&symbol=VKTX&cdn=a1f258bfbf8c64f83122b822569029c4&companyName=Viking+Therapeutics+Inc.&formType=8-K&dateFiled=2024-11-04)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Report of unscheduled material events or corporate event in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318684372&type=PDF&symbol=VKTX&cdn=a1f258bfbf8c64f83122b822569029c4&companyName=Viking+Therapeutics+Inc.&formType=8-K&dateFiled=2024-11-04)[![](images/webdriver/fileicons/16/sec_xls.png)Open Report of unscheduled material events or corporate event in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318684372&type=XLS&symbol=VKTX&cdn=a1f258bfbf8c64f83122b822569029c4&companyName=Viking+Therapeutics+Inc.&formType=8-K&dateFiled=2024-11-04)[![](images/webdriver/fileicons/16/sec_xbrl.png)Open Report of unscheduled material events or corporate event in XBLR Viewer.](#)[![](images/webdriver/fileicons/16/sec_xbrl_download.png)Open Report of unscheduled material events or corporate event in XBLR file.](#)  \n4| Statement of changes in beneficial ownership of securities| Oct 28, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Statement of changes in beneficial ownership of securities in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318669431&type=HTML&symbol=VKTX&cdn=ed75781efd818145e70af6f62ca64978&companyName=Viking+Therapeutics+Inc.&formType=4&dateFiled=2024-10-28)[![](images/webdriver/fileicons/16/sec_doc.png)Open Statement of changes in beneficial ownership of securities in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318669431&type=DOC&symbol=VKTX&cdn=ed75781efd818145e70af6f62ca64978&companyName=Viking+Therapeutics+Inc.&formType=4&dateFiled=2024-10-28)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Statement of changes in beneficial ownership of securities in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318669431&type=PDF&symbol=VKTX&cdn=ed75781efd818145e70af6f62ca64978&companyName=Viking+Therapeutics+Inc.&formType=4&dateFiled=2024-10-28)[![](images/webdriver/fileicons/16/sec_xls.png)Open Statement of changes in beneficial ownership of securities in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318669431&type=XLS&symbol=VKTX&cdn=ed75781efd818145e70af6f62ca64978&companyName=Viking+Therapeutics+Inc.&formType=4&dateFiled=2024-10-28)  \n144| Non-EDGAR filing submitted by \"insiders\" prior to intended sale of restricted stock| Oct 28, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Non-EDGAR filing submitted by \"insiders\" prior to intended sale of restricted stock in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318668813&type=HTML&symbol=VKTX&cdn=e4cba874e1fc34d6c8aff6a232eeda70&companyName=Viking+Therapeutics+Inc.&formType=144&dateFiled=2024-10-28)[![](images/webdriver/fileicons/16/sec_doc.png)Open Non-EDGAR filing submitted by \"insiders\" prior to intended sale of restricted stock in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318668813&type=DOC&symbol=VKTX&cdn=e4cba874e1fc34d6c8aff6a232eeda70&companyName=Viking+Therapeutics+Inc.&formType=144&dateFiled=2024-10-28)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Non-EDGAR filing submitted by \"insiders\" prior to intended sale of restricted stock in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318668813&type=PDF&symbol=VKTX&cdn=e4cba874e1fc34d6c8aff6a232eeda70&companyName=Viking+Therapeutics+Inc.&formType=144&dateFiled=2024-10-28)[![](images/webdriver/fileicons/16/sec_xls.png)Open Non-EDGAR filing submitted by \"insiders\" prior to intended sale of restricted stock in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318668813&type=XLS&symbol=VKTX&cdn=e4cba874e1fc34d6c8aff6a232eeda70&companyName=Viking+Therapeutics+Inc.&formType=144&dateFiled=2024-10-28)  \n4| Statement of changes in beneficial ownership of securities| Oct 25, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Statement of changes in beneficial ownership of securities in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318666062&type=HTML&symbol=VKTX&cdn=c65ac0b54bb88a74b2b9bf2a8db07699&companyName=Viking+Therapeutics+Inc.&formType=4&dateFiled=2024-10-25)[![](images/webdriver/fileicons/16/sec_doc.png)Open Statement of changes in beneficial ownership of securities in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318666062&type=DOC&symbol=VKTX&cdn=c65ac0b54bb88a74b2b9bf2a8db07699&companyName=Viking+Therapeutics+Inc.&formType=4&dateFiled=2024-10-25)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Statement of changes in beneficial ownership of securities in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318666062&type=PDF&symbol=VKTX&cdn=c65ac0b54bb88a74b2b9bf2a8db07699&companyName=Viking+Therapeutics+Inc.&formType=4&dateFiled=2024-10-25)[![](images/webdriver/fileicons/16/sec_xls.png)Open Statement of changes in beneficial ownership of securities in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318666062&type=XLS&symbol=VKTX&cdn=c65ac0b54bb88a74b2b9bf2a8db07699&companyName=Viking+Therapeutics+Inc.&formType=4&dateFiled=2024-10-25)  \n4| Statement of changes in beneficial ownership of securities| Oct 25, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Statement of changes in beneficial ownership of securities in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318666063&type=HTML&symbol=VKTX&cdn=98d98f81ba7ac7ea021ba92f8c921ccd&companyName=Viking+Therapeutics+Inc.&formType=4&dateFiled=2024-10-25)[![](images/webdriver/fileicons/16/sec_doc.png)Open Statement of changes in beneficial ownership of securities in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318666063&type=DOC&symbol=VKTX&cdn=98d98f81ba7ac7ea021ba92f8c921ccd&companyName=Viking+Therapeutics+Inc.&formType=4&dateFiled=2024-10-25)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Statement of changes in beneficial ownership of securities in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318666063&type=PDF&symbol=VKTX&cdn=98d98f81ba7ac7ea021ba92f8c921ccd&companyName=Viking+Therapeutics+Inc.&formType=4&dateFiled=2024-10-25)[![](images/webdriver/fileicons/16/sec_xls.png)Open Statement of changes in beneficial ownership of securities in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318666063&type=XLS&symbol=VKTX&cdn=98d98f81ba7ac7ea021ba92f8c921ccd&companyName=Viking+Therapeutics+Inc.&formType=4&dateFiled=2024-10-25)  \n144| Non-EDGAR filing submitted by \"insiders\" prior to intended sale of restricted stock| Oct 25, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Non-EDGAR filing submitted by \"insiders\" prior to intended sale of restricted stock in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318665236&type=HTML&symbol=VKTX&cdn=6883b1d08c0a38b2172840010dde3be7&companyName=Viking+Therapeutics+Inc.&formType=144&dateFiled=2024-10-25)[![](images/webdriver/fileicons/16/sec_doc.png)Open Non-EDGAR filing submitted by \"insiders\" prior to intended sale of restricted stock in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318665236&type=DOC&symbol=VKTX&cdn=6883b1d08c0a38b2172840010dde3be7&companyName=Viking+Therapeutics+Inc.&formType=144&dateFiled=2024-10-25)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Non-EDGAR filing submitted by \"insiders\" prior to intended sale of restricted stock in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318665236&type=PDF&symbol=VKTX&cdn=6883b1d08c0a38b2172840010dde3be7&companyName=Viking+Therapeutics+Inc.&formType=144&dateFiled=2024-10-25)[![](images/webdriver/fileicons/16/sec_xls.png)Open Non-EDGAR filing submitted by \"insiders\" prior to intended sale of restricted stock in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318665236&type=XLS&symbol=VKTX&cdn=6883b1d08c0a38b2172840010dde3be7&companyName=Viking+Therapeutics+Inc.&formType=144&dateFiled=2024-10-25)  \n144| Non-EDGAR filing submitted by \"insiders\" prior to intended sale of restricted stock| Oct 25, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Non-EDGAR filing submitted by \"insiders\" prior to intended sale of restricted stock in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318665335&type=HTML&symbol=VKTX&cdn=944ac387ce5f61df5cb229a5a654c2b5&companyName=Viking+Therapeutics+Inc.&formType=144&dateFiled=2024-10-25)[![](images/webdriver/fileicons/16/sec_doc.png)Open Non-EDGAR filing submitted by \"insiders\" prior to intended sale of restricted stock in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318665335&type=DOC&symbol=VKTX&cdn=944ac387ce5f61df5cb229a5a654c2b5&companyName=Viking+Therapeutics+Inc.&formType=144&dateFiled=2024-10-25)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Non-EDGAR filing submitted by \"insiders\" prior to intended sale of restricted stock in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318665335&type=PDF&symbol=VKTX&cdn=944ac387ce5f61df5cb229a5a654c2b5&companyName=Viking+Therapeutics+Inc.&formType=144&dateFiled=2024-10-25)[![](images/webdriver/fileicons/16/sec_xls.png)Open Non-EDGAR filing submitted by \"insiders\" prior to intended sale of restricted stock in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318665335&type=XLS&symbol=VKTX&companyName=Viking+Therapeutics+Inc.&formType=144&dateFiled=2024-10-25)  \n10-Q| Quarterly report which provides a continuing view of a company's financial position| Oct 23, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Quarterly report which provides a continuing view of a company's financial position in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318660304&type=HTML&symbol=VKTX&cdn=bcbaac7a817b0b056ffcca8329a742c9&companyName=Viking+Therapeutics+Inc.&formType=10-Q&dateFiled=2024-10-23)[![](images/webdriver/fileicons/16/sec_doc.png)Open Quarterly report which provides a continuing view of a company's financial position in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318660304&type=DOC&symbol=VKTX&cdn=bcbaac7a817b0b056ffcca8329a742c9&companyName=Viking+Therapeutics+Inc.&formType=10-Q&dateFiled=2024-10-23)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Quarterly report which provides a continuing view of a company's financial position in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318660304&type=PDF&symbol=VKTX&cdn=bcbaac7a817b0b056ffcca8329a742c9&companyName=Viking+Therapeutics+Inc.&formType=10-Q&dateFiled=2024-10-23)[![](images/webdriver/fileicons/16/sec_xls.png)Open Quarterly report which provides a continuing view of a company's financial position in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318660304&type=XLS&symbol=VKTX&cdn=bcbaac7a817b0b056ffcca8329a742c9&companyName=Viking+Therapeutics+Inc.&formType=10-Q&dateFiled=2024-10-23)[![](images/webdriver/fileicons/16/sec_xbrl.png)Open Quarterly report which provides a continuing view of a company's financial position in XBLR Viewer.](#)[![](images/webdriver/fileicons/16/sec_xbrl_download.png)Open Quarterly report which provides a continuing view of a company's financial position in XBLR file.](#)  \n8-K| Report of unscheduled material events or corporate event| Oct 23, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Report of unscheduled material events or corporate event in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318659919&type=HTML&symbol=VKTX&cdn=43cf6ff01a84e74d68e0d5c39d7c7278&companyName=Viking+Therapeutics+Inc.&formType=8-K&dateFiled=2024-10-23)[![](images/webdriver/fileicons/16/sec_doc.png)Open Report of unscheduled material events or corporate event in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318659919&type=DOC&symbol=VKTX&cdn=43cf6ff01a84e74d68e0d5c39d7c7278&companyName=Viking+Therapeutics+Inc.&formType=8-K&dateFiled=2024-10-23)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Report of unscheduled material events or corporate event in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318659919&type=PDF&symbol=VKTX&cdn=43cf6ff01a84e74d68e0d5c39d7c7278&companyName=Viking+Therapeutics+Inc.&formType=8-K&dateFiled=2024-10-23)[![](images/webdriver/fileicons/16/sec_xls.png)Open Report of unscheduled material events or corporate event in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318659919&type=XLS&symbol=VKTX&cdn=43cf6ff01a84e74d68e0d5c39d7c7278&companyName=Viking+Therapeutics+Inc.&formType=8-K&dateFiled=2024-10-23)[![](images/webdriver/fileicons/16/sec_xbrl.png)Open Report of unscheduled material events or corporate event in XBLR Viewer.](#)[![](images/webdriver/fileicons/16/sec_xbrl_download.png)Open Report of unscheduled material events or corporate event in XBLR file.](#)  \nSC 13G/A| Amendment to a previously filed SC 13G| Oct 18, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Amendment to a previously filed SC 13G in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318652207&type=HTML&symbol=VKTX&cdn=8bb14b2bc2f27f1f59bfce84b800a586&companyName=Viking+Therapeutics+Inc.&formType=SC+13G%2FA&dateFiled=2024-10-18)[![](images/webdriver/fileicons/16/sec_doc.png)Open Amendment to a previously filed SC 13G in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318652207&type=DOC&symbol=VKTX&cdn=8bb14b2bc2f27f1f59bfce84b800a586&companyName=Viking+Therapeutics+Inc.&formType=SC+13G%2FA&dateFiled=2024-10-18)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Amendment to a previously filed SC 13G in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318652207&type=PDF&symbol=VKTX&cdn=8bb14b2bc2f27f1f59bfce84b800a586&companyName=Viking+Therapeutics+Inc.&formType=SC+13G%2FA&dateFiled=2024-10-18)[![](images/webdriver/fileicons/16/sec_xls.png)Open Amendment to a previously filed SC 13G in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318652207&type=XLS&symbol=VKTX&cdn=8bb14b2bc2f27f1f59bfce84b800a586&companyName=Viking+Therapeutics+Inc.&formType=SC+13G%2FA&dateFiled=2024-10-18)  \n4| Statement of changes in beneficial ownership of securities| Sep 20, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Statement of changes in beneficial ownership of securities in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318603278&type=HTML&symbol=VKTX&cdn=43e8463c56bd9555a31ac3e92ca61404&companyName=Viking+Therapeutics+Inc.&formType=4&dateFiled=2024-09-20)[![](images/webdriver/fileicons/16/sec_doc.png)Open Statement of changes in beneficial ownership of securities in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318603278&type=DOC&symbol=VKTX&cdn=43e8463c56bd9555a31ac3e92ca61404&companyName=Viking+Therapeutics+Inc.&formType=4&dateFiled=2024-09-20)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Statement of changes in beneficial ownership of securities in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318603278&type=PDF&symbol=VKTX&cdn=43e8463c56bd9555a31ac3e92ca61404&companyName=Viking+Therapeutics+Inc.&formType=4&dateFiled=2024-09-20)[![](images/webdriver/fileicons/16/sec_xls.png)Open Statement of changes in beneficial ownership of securities in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318603278&type=XLS&symbol=VKTX&cdn=43e8463c56bd9555a31ac3e92ca61404&companyName=Viking+Therapeutics+Inc.&formType=4&dateFiled=2024-09-20)  \n4| Statement of changes in beneficial ownership of securities| Sep 20, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Statement of changes in beneficial ownership of securities in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318603285&type=HTML&symbol=VKTX&cdn=abbe893f2efac966cdc03e15d77dff94&companyName=Viking+Therapeutics+Inc.&formType=4&dateFiled=2024-09-20)[![](images/webdriver/fileicons/16/sec_doc.png)Open Statement of changes in beneficial ownership of securities in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318603285&type=DOC&symbol=VKTX&cdn=abbe893f2efac966cdc03e15d77dff94&companyName=Viking+Therapeutics+Inc.&formType=4&dateFiled=2024-09-20)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Statement of changes in beneficial ownership of securities in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318603285&type=PDF&symbol=VKTX&cdn=abbe893f2efac966cdc03e15d77dff94&companyName=Viking+Therapeutics+Inc.&formType=4&dateFiled=2024-09-20)[![](images/webdriver/fileicons/16/sec_xls.png)Open Statement of changes in beneficial ownership of securities in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318603285&type=XLS&symbol=VKTX&cdn=abbe893f2efac966cdc03e15d77dff94&companyName=Viking+Therapeutics+Inc.&formType=4&dateFiled=2024-09-20)  \n144| Non-EDGAR filing submitted by \"insiders\" prior to intended sale of restricted stock| Sep 20, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Non-EDGAR filing submitted by \"insiders\" prior to intended sale of restricted stock in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318602741&type=HTML&symbol=VKTX&cdn=37738a6a40815dd7d4e3e0a41f016149&companyName=Viking+Therapeutics+Inc.&formType=144&dateFiled=2024-09-20)[![](images/webdriver/fileicons/16/sec_doc.png)Open Non-EDGAR filing submitted by \"insiders\" prior to intended sale of restricted stock in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318602741&type=DOC&symbol=VKTX&cdn=37738a6a40815dd7d4e3e0a41f016149&companyName=Viking+Therapeutics+Inc.&formType=144&dateFiled=2024-09-20)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Non-EDGAR filing submitted by \"insiders\" prior to intended sale of restricted stock in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318602741&type=PDF&symbol=VKTX&cdn=37738a6a40815dd7d4e3e0a41f016149&companyName=Viking+Therapeutics+Inc.&formType=144&dateFiled=2024-09-20)[![](images/webdriver/fileicons/16/sec_xls.png)Open Non-EDGAR filing submitted by \"insiders\" prior to intended sale of restricted stock in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318602741&type=XLS&symbol=VKTX&cdn=37738a6a40815dd7d4e3e0a41f016149&companyName=Viking+Therapeutics+Inc.&formType=144&dateFiled=2024-09-20)  \n144| Non-EDGAR filing submitted by \"insiders\" prior to intended sale of restricted stock| Sep 20, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Non-EDGAR filing submitted by \"insiders\" prior to intended sale of restricted stock in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318602557&type=HTML&symbol=VKTX&cdn=76e8ba991f25b7e6ac7bbc0aba081788&companyName=Viking+Therapeutics+Inc.&formType=144&dateFiled=2024-09-20)[![](images/webdriver/fileicons/16/sec_doc.png)Open Non-EDGAR filing submitted by \"insiders\" prior to intended sale of restricted stock in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318602557&type=DOC&symbol=VKTX&cdn=76e8ba991f25b7e6ac7bbc0aba081788&companyName=Viking+Therapeutics+Inc.&formType=144&dateFiled=2024-09-20)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Non-EDGAR filing submitted by \"insiders\" prior to intended sale of restricted stock in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318602557&type=PDF&symbol=VKTX&cdn=76e8ba991f25b7e6ac7bbc0aba081788&companyName=Viking+Therapeutics+Inc.&formType=144&dateFiled=2024-09-20)[![](images/webdriver/fileicons/16/sec_xls.png)Open Non-EDGAR filing submitted by \"insiders\" prior to intended sale of restricted stock in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318602557&type=XLS&symbol=VKTX&cdn=76e8ba991f25b7e6ac7bbc0aba081788&companyName=Viking+Therapeutics+Inc.&formType=144&dateFiled=2024-09-20)  \n4| Statement of changes in beneficial ownership of securities| Aug 22, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Statement of changes in beneficial ownership of securities in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318542970&type=HTML&symbol=VKTX&cdn=7f7d5ec7c892d4c0342380d1591b9b7e&companyName=Viking+Therapeutics+Inc.&formType=4&dateFiled=2024-08-22)[![](images/webdriver/fileicons/16/sec_doc.png)Open Statement of changes in beneficial ownership of securities in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318542970&type=DOC&symbol=VKTX&cdn=7f7d5ec7c892d4c0342380d1591b9b7e&companyName=Viking+Therapeutics+Inc.&formType=4&dateFiled=2024-08-22)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Statement of changes in beneficial ownership of securities in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318542970&type=PDF&symbol=VKTX&cdn=7f7d5ec7c892d4c0342380d1591b9b7e&companyName=Viking+Therapeutics+Inc.&formType=4&dateFiled=2024-08-22)[![](images/webdriver/fileicons/16/sec_xls.png)Open Statement of changes in beneficial ownership of securities in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318542970&type=XLS&symbol=VKTX&cdn=7f7d5ec7c892d4c0342380d1591b9b7e&companyName=Viking+Therapeutics+Inc.&formType=4&dateFiled=2024-08-22)  \n4| Statement of changes in beneficial ownership of securities| Aug 22, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Statement of changes in beneficial ownership of securities in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318542968&type=HTML&symbol=VKTX&cdn=eb3ee70243a14cdab4caac540240c390&companyName=Viking+Therapeutics+Inc.&formType=4&dateFiled=2024-08-22)[![](images/webdriver/fileicons/16/sec_doc.png)Open Statement of changes in beneficial ownership of securities in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318542968&type=DOC&symbol=VKTX&cdn=eb3ee70243a14cdab4caac540240c390&companyName=Viking+Therapeutics+Inc.&formType=4&dateFiled=2024-08-22)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Statement of changes in beneficial ownership of securities in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318542968&type=PDF&symbol=VKTX&cdn=eb3ee70243a14cdab4caac540240c390&companyName=Viking+Therapeutics+Inc.&formType=4&dateFiled=2024-08-22)[![](images/webdriver/fileicons/16/sec_xls.png)Open Statement of changes in beneficial ownership of securities in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318542968&type=XLS&symbol=VKTX&cdn=eb3ee70243a14cdab4caac540240c390&companyName=Viking+Therapeutics+Inc.&formType=4&dateFiled=2024-08-22)  \n144| Non-EDGAR filing submitted by \"insiders\" prior to intended sale of restricted stock| Aug 21, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Non-EDGAR filing submitted by \"insiders\" prior to intended sale of restricted stock in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318539859&type=HTML&symbol=VKTX&cdn=d5ab49e5013672c0d25c7dd1b1b0ccae&companyName=Viking+Therapeutics+Inc.&formType=144&dateFiled=2024-08-21)[![](images/webdriver/fileicons/16/sec_doc.png)Open Non-EDGAR filing submitted by \"insiders\" prior to intended sale of restricted stock in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318539859&type=DOC&symbol=VKTX&cdn=d5ab49e5013672c0d25c7dd1b1b0ccae&companyName=Viking+Therapeutics+Inc.&formType=144&dateFiled=2024-08-21)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Non-EDGAR filing submitted by \"insiders\" prior to intended sale of restricted stock in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318539859&type=PDF&symbol=VKTX&cdn=d5ab49e5013672c0d25c7dd1b1b0ccae&companyName=Viking+Therapeutics+Inc.&formType=144&dateFiled=2024-08-21)[![](images/webdriver/fileicons/16/sec_xls.png)Open Non-EDGAR filing submitted by \"insiders\" prior to intended sale of restricted stock in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318539859&type=XLS&symbol=VKTX&cdn=d5ab49e5013672c0d25c7dd1b1b0ccae&companyName=Viking+Therapeutics+Inc.&formType=144&dateFiled=2024-08-21)  \n144| Non-EDGAR filing submitted by \"insiders\" prior to intended sale of restricted stock| Aug 21, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Non-EDGAR filing submitted by \"insiders\" prior to intended sale of restricted stock in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318539721&type=HTML&symbol=VKTX&cdn=df75d0a358ccdd7600b1bcf9bb4b442d&companyName=Viking+Therapeutics+Inc.&formType=144&dateFiled=2024-08-21)[![](images/webdriver/fileicons/16/sec_doc.png)Open Non-EDGAR filing submitted by \"insiders\" prior to intended sale of restricted stock in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318539721&type=DOC&symbol=VKTX&cdn=df75d0a358ccdd7600b1bcf9bb4b442d&companyName=Viking+Therapeutics+Inc.&formType=144&dateFiled=2024-08-21)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Non-EDGAR filing submitted by \"insiders\" prior to intended sale of restricted stock in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318539721&type=PDF&symbol=VKTX&cdn=df75d0a358ccdd7600b1bcf9bb4b442d&companyName=Viking+Therapeutics+Inc.&formType=144&dateFiled=2024-08-21)[![](images/webdriver/fileicons/16/sec_xls.png)Open Non-EDGAR filing submitted by \"insiders\" prior to intended sale of restricted stock in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318539721&type=XLS&symbol=VKTX&cdn=df75d0a358ccdd7600b1bcf9bb4b442d&companyName=Viking+Therapeutics+Inc.&formType=144&dateFiled=2024-08-21)  \n4| Statement of changes in beneficial ownership of securities| Aug 19, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Statement of changes in beneficial ownership of securities in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318534523&type=HTML&symbol=VKTX&cdn=f24c63fd533855df2dcf3b3fa58f2049&companyName=Viking+Therapeutics+Inc.&formType=4&dateFiled=2024-08-19)[![](images/webdriver/fileicons/16/sec_doc.png)Open Statement of changes in beneficial ownership of securities in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318534523&type=DOC&symbol=VKTX&cdn=f24c63fd533855df2dcf3b3fa58f2049&companyName=Viking+Therapeutics+Inc.&formType=4&dateFiled=2024-08-19)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Statement of changes in beneficial ownership of securities in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318534523&type=PDF&symbol=VKTX&cdn=f24c63fd533855df2dcf3b3fa58f2049&companyName=Viking+Therapeutics+Inc.&formType=4&dateFiled=2024-08-19)[![](images/webdriver/fileicons/16/sec_xls.png)Open Statement of changes in beneficial ownership of securities in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318534523&type=XLS&symbol=VKTX&cdn=f24c63fd533855df2dcf3b3fa58f2049&companyName=Viking+Therapeutics+Inc.&formType=4&dateFiled=2024-08-19)  \n4| Statement of changes in beneficial ownership of securities| Aug 19, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Statement of changes in beneficial ownership of securities in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318534521&type=HTML&symbol=VKTX&cdn=bf719fa32cc67c920b5ab268aad7a85c&companyName=Viking+Therapeutics+Inc.&formType=4&dateFiled=2024-08-19)[![](images/webdriver/fileicons/16/sec_doc.png)Open Statement of changes in beneficial ownership of securities in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318534521&type=DOC&symbol=VKTX&cdn=bf719fa32cc67c920b5ab268aad7a85c&companyName=Viking+Therapeutics+Inc.&formType=4&dateFiled=2024-08-19)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Statement of changes in beneficial ownership of securities in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318534521&type=PDF&symbol=VKTX&cdn=bf719fa32cc67c920b5ab268aad7a85c&companyName=Viking+Therapeutics+Inc.&formType=4&dateFiled=2024-08-19)[![](images/webdriver/fileicons/16/sec_xls.png)Open Statement of changes in beneficial ownership of securities in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318534521&type=XLS&symbol=VKTX&cdn=bf719fa32cc67c920b5ab268aad7a85c&companyName=Viking+Therapeutics+Inc.&formType=4&dateFiled=2024-08-19)  \n**1-25[26-50](https://ir.vikingtherapeutics.com/index.php?o=25&s=127) [51-75](https://ir.vikingtherapeutics.com/index.php?o=50&s=127) [76-100](https://ir.vikingtherapeutics.com/index.php?o=75&s=127) [101-103](https://ir.vikingtherapeutics.com/index.php?o=100&s=127)**  \n  \n  * [](#print \"print\")\n  * [](#email \"email\")\n\n\n\n[Trailing 12-Months](https://ir.vikingtherapeutics.com/sec-filings?year=)[Calendar Year 2024](https://ir.vikingtherapeutics.com/sec-filings?year=2024)[Calendar Year 2023](https://ir.vikingtherapeutics.com/sec-filings?year=2023)[Calendar Year 2022](https://ir.vikingtherapeutics.com/sec-filings?year=2022)[Calendar Year 2021](https://ir.vikingtherapeutics.com/sec-filings?year=2021)[Calendar Year 2020](https://ir.vikingtherapeutics.com/sec-filings?year=2020)[Calendar Year 2019](https://ir.vikingtherapeutics.com/sec-filings?year=2019)[Calendar Year 2018](https://ir.vikingtherapeutics.com/sec-filings?year=2018)[Calendar Year 2017](https://ir.vikingtherapeutics.com/sec-filings?year=2017)[Calendar Year 2016](https://ir.vikingtherapeutics.com/sec-filings?year=2016)[Calendar Year 2015](https://ir.vikingtherapeutics.com/sec-filings?year=2015)[Calendar Year 2014](https://ir.vikingtherapeutics.com/sec-filings?year=2014)[All Filings](https://ir.vikingtherapeutics.com/sec-filings?cat=)[Annual Filings](https://ir.vikingtherapeutics.com/sec-filings?cat=1)[Quarterly Filings](https://ir.vikingtherapeutics.com/sec-filings?cat=2)[Current Filings](https://ir.vikingtherapeutics.com/sec-filings?cat=3)[Registration Statements](https://ir.vikingtherapeutics.com/sec-filings?cat=4)[Section 16](https://ir.vikingtherapeutics.com/sec-filings?cat=5)[Proxy & Information Statements](https://ir.vikingtherapeutics.com/sec-filings?cat=7)[Other](https://ir.vikingtherapeutics.com/sec-filings?cat=8)\n"
        }
      ]
    },
    {
      "section_name": "Corporate Presentation",
      "links": [
        {
          "title": "Corporate Presentation",
          "url": "https://ir.vikingtherapeutics.com/corporatepresentation",
          "content": "[![Viking Therapeutics](https://www.vikingtherapeutics.com/wp-content/uploads/viking-logo-top-3.png)](http://www.vikingtherapeutics.com/)\n\n# Corporate Presentation \n\n![Investors](images/section-stock-1024x262.jpg)\n\n  * [ Overview ](https://ir.vikingtherapeutics.com/overview)\n  * [ Stock Information ](https://ir.vikingtherapeutics.com/stock-information)\n  * [ News & Events ](press-releases)\n  * [ SEC Filings ](https://ir.vikingtherapeutics.com/sec-filings)\n  * [ Analyst Coverage ](https://ir.vikingtherapeutics.com/analyst-coverage)\n  * [ Corporate Governance ](governance-highlights)\n  * [ Shareholder Services ](information-request)\n  * [ Corporate Presentation ](https://ir.vikingtherapeutics.com/corporatepresentation)\n\n[Sign Up for Email Alerts](email-alerts) [Investor Relations Contacts](ir-contacts)\n\n![](/image/Corp+Presentation+-+Cover+for+websiteTHWS3.jpg)  \n---  \n  \n[![](http://ir.vikingtherapeutics.com/image/PDF-iconupdated.png)](download/Viking+Therapeutics+Corporate+Presentation+October+2024.pdf)\n\n[Download Corporate Presentation](download/Viking+Therapeutics+Corporate+Presentation+October+2024.pdf)\n\n  * [](#print \"print\")\n  * [](#email \"email\")\n\n\n"
        }
      ]
    }
  ]
}